Natural Killer cells and monoclonal antibodies: Two partners for successful antibody dependent cytotoxicity against tumor cells

Monoclonal antibodies targeting tumors are one of the most important discoveries in field cancer. Although several effective have been developed, a relapse may occur. One their mechanisms action is Antibody Dependent Cell Cytotoxicity (ADCC), by engaging Fc γ receptor CD16 expressing Natural Killer cells, innate lymphoid cells involved cancer immunosurveillance and able to kill tumor cells. A lack NK observed many cancers therefore be cause low efficacy some clinical situations. Here we review clear evidences essential partnership between showed vitro, vivo, trials different indications, describe hurdles ways enhance ADCC evolution monoclonal antibody therapy. cell adoptive immunotherapy combined with overcome resistance treatment efficacy.